Themis starts Phase II trial of Chikungunya vaccine in the U.S.8. June 2017|In Portfolio News|By eazee-designstudioSponsored by the National Institutes of Health, Themis Bioscience started a Phase II trial of its Chikungunya vaccine on a candidate in the U.S. PrevNext
